Role of Endothelial Dysfunction in Atherosclerosis

Ovid Technologies (Wolters Kluwer Health) - Tập 109 Số 23_suppl_1 - 2004
Jean Davignon1, Peter Ganz1
1From the Hyperlipidemia and Atherosclerosis Research Group/Groupe de recherche sur les hyperlipidémies et l’athérosclérose, Clinical Research Institute of Montreal/Institut de recherches cliniques de Montréal (IRCM) (J.D.), Montreal, Canada; and the Cardiovascular Division (P.G.), Brigham and Women’s Hospital, Boston, Mass.

Tóm tắt

As the major regulator of vascular homeostasis, the endothelium exerts a number of vasoprotective effects, such as vasodilation, suppression of smooth muscle cell growth, and inhibition of inflammatory responses. Many of these effects are largely mediated by nitric oxide, the most potent endogenous vasodilator. Nitric oxide opposes the effects of endothelium-derived vasoconstrictors and inhibits oxidation of low-density lipoprotein. A defect in the production or activity of nitric oxide leads to endothelial dysfunction, signaled by impaired endothelium-dependent vasodilation. Accumulating evidence suggests that endothelial dysfunction is an early marker for atherosclerosis and can be detected before structural changes to the vessel wall are apparent on angiography or ultrasound. Many of the risk factors that predispose to atherosclerosis can also cause endothelial dysfunction, and the presence of multiple risk factors has been found to predict endothelial dysfunction. A number of clinical trials have shown that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) improve endothelial dysfunction in patients with coronary risk factors beyond what could be attributed to their impact on plasma lipids. Studies have elucidated several possible mechanisms by which statin therapy may improve endothelial dysfunction, including upregulation of nitric oxide production or activity and reduction of oxidative stress.

Từ khóa


Tài liệu tham khảo

1997, Clin Cardiol, 20, II-3

10.1097/00041433-200108000-00003

10.1016/S0002-9149(98)00769-3

10.1056/NEJMe020054

10.1161/circ.104.10.1114

10.1056/NEJM199901143400207

10.1016/S0002-9149(02)02963-6

10.1161/atvb.20.9.2032

10.1515/BC.2002.055

10.1161/01.cir.0000014762.06201.06

10.1161/circ.103.15.1955

10.1073/pnas.95.15.8880

10.1161/01.res.0000049166.33035.62

10.1016/S0735-1097(97)00189-7

10.1056/NEJM198610233151702

10.1016/S0002-9149(99)80531-1

2000, J Am Coll Cardiol, 39, 257

10.1161/circ.102.9.1000

10.1016/0735-1097(94)90627-0

10.1016/0735-1097(94)90141-4

10.1161/circ.91.9.2345

10.1161/circ.98.3.211

10.1161/circ.81.2.2105174

10.1161/circ.100.14.1502

10.1161/circ.97.25.2519

10.1016/S0735-1097(98)82203-1

10.1016/S0895-7061(02)03027-3

10.1161/circ.101.9.948

10.1161/circ.101.16.1899

10.1161/01.cir.0000025404.78001.d8

10.1161/circ.104.22.2673

10.1016/S0002-9149(00)00857-2

10.1097/00019501-200111000-00002

10.1161/circ.89.6.8205659

10.1056/NEJM199502233320801

10.1097/00005344-200011000-00011

1995, Am J Cardiol, 76, 122A, 10.1016/S0002-9149(05)80033-5

10.1161/circ.95.5.1126

10.1161/circ.99.25.3227

10.1016/S0002-9149(01)02095-1

10.1161/circ.89.4.8149518

2000, Am J Cardiol, 86, 10J

10.1161/circ.102.8.846

10.1001/jama.279.20.1643

10.1016/S0002-9149(01)02090-2

2001, Arterioscler Thromb Vasc Biol, 5, 804

10.1161/01.CIR.103.1.113

10.1161/circ.97.12.1129

10.1161/res.87.7.526

2000, J Investig Med, 48, 183

10.1038/79510

10.1056/NEJM199502233320802

10.1056/NEJM199708073370601

10.1016/S0140-6736(02)09328-5

10.1016/S0021-9150(98)00032-X

10.1016/S0021-9150(02)00063-1

Thông tin
Thông tin xuất bản

Ovid Technologies (Wolters Kluwer Health)

Tập 109 Số 23_suppl_1

Thông tin tác giả